Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis.

Hepatology research : the official journal of the Japan Society of Hepatology

Kasprzak A, Adamek A.
PMID: 17894800
Hepatol Res. 2008 Jan;38(1):1-26. doi: 10.1111/j.1872-034X.2007.00261.x. Epub 2007 Sep 25.

In recent years, the effects of hepatitis C virus (HCV) proteins on hepatocarcinogenesis have undergone intense investigations. The potentially oncogenic proteins include at least three HCV proteins: core (C) protein, NS3, and NS5A. Several authors indicated relationships between subcellular...

Cite
Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res. 2007;38(1):1-26doi: 10.1111/j.1872-034X.2007.00261.x.
Kasprzak, A., & Adamek, A. (2008). Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatology research : the official journal of the Japan Society of Hepatology, 38(1), 1-26. https://doi.org/10.1111/j.1872-034X.2007.00261.x
Kasprzak, Aldona, and Adamek, Agnieszka. "Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 38,1 (2008): 1-26. doi: https://doi.org/10.1111/j.1872-034X.2007.00261.x
Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res. 2008 Jan;38(1):1-26. doi: 10.1111/j.1872-034X.2007.00261.x. Epub 2007 Sep 25. PMID: 17894800.
Copy Download .nbib Format: NLM
Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C.

Contemporary oncology (Poznan, Poland)

Adamek A, Kasprzak A, Seraszek A, Mikoś H, Bura A, Mozer-Lisewska I.
PMID: 23788886
Contemp Oncol (Pozn). 2012;16(3):234-9. doi: 10.5114/wo.2012.29291. Epub 2012 Jul 06.

AIM OF THE STUDY: Deregulation of insulin-like growth factor I (IGF-I) production and decreased hepatic estrogen levels were associated with development of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) infected cirrhotic patients. The aim of our study was...

Cite
Adamek A, Kasprzak A, Seraszek A, et al. Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. Contemp Oncol (Pozn). 2012;16(3):234-9doi: 10.5114/wo.2012.29291.
Adamek, A., Kasprzak, A., Seraszek, A., Mikoś, H., Bura, A., & Mozer-Lisewska, I. (2012). Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. Contemporary oncology (Poznan, Poland), 16(3), 234-9. https://doi.org/10.5114/wo.2012.29291
Adamek, Agnieszka, et al. "Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C." Contemporary oncology (Poznan, Poland) vol. 16,3 (2012): 234-9. doi: https://doi.org/10.5114/wo.2012.29291
Adamek A, Kasprzak A, Seraszek A, Mikoś H, Bura A, Mozer-Lisewska I. Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. Contemp Oncol (Pozn). 2012;16(3):234-9. doi: 10.5114/wo.2012.29291. Epub 2012 Jul 06. PMID: 23788886; PMCID: PMC3687405.
Copy Download .nbib Format: NLM
Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study.

Journal of clinical medicine

Olewicz-Gawlik A, Ginter-Matuszewska B, Kamiński M, Adamek A, Bura M, Mozer-Lisewska I, Kowala-Piaskowska A.
PMID: 35011848
J Clin Med. 2021 Dec 25;11(1). doi: 10.3390/jcm11010107.

The COVID-19 pandemic requires the development of effective methods for the treatment of severe cases. We aimed to describe clinical outcomes and changes in inflammatory markers in Polish patients treated with tocilizumab. The medical charts of SARS-CoV-2-positive patients treated...

Cite
Olewicz-Gawlik A, Ginter-Matuszewska B, Kamiński M, et al. Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study. J Clin Med. 2021;11(1)doi: 10.3390/jcm11010107.
Olewicz-Gawlik, A., Ginter-Matuszewska, B., Kamiński, M., Adamek, A., Bura, M., Mozer-Lisewska, I., & Kowala-Piaskowska, A. (2021). Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study. Journal of clinical medicine, 11(1), . https://doi.org/10.3390/jcm11010107
Olewicz-Gawlik, Anna, et al. "Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study." Journal of clinical medicine vol. 11,1 (2021). doi: https://doi.org/10.3390/jcm11010107
Olewicz-Gawlik A, Ginter-Matuszewska B, Kamiński M, Adamek A, Bura M, Mozer-Lisewska I, Kowala-Piaskowska A. Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study. J Clin Med. 2021 Dec 25;11(1). doi: 10.3390/jcm11010107. PMID: 35011848; PMCID: PMC8745724.
Copy Download .nbib Format: NLM
Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study.

Journal of clinical medicine

Olewicz-Gawlik A, Ginter-Matuszewska B, Kamiński M, Adamek A, Bura M, Mozer-Lisewska I, Kowala-Piaskowska A.
PMID: 35011848
J Clin Med. 2021 Dec 25;11(1). doi: 10.3390/jcm11010107.

The COVID-19 pandemic requires the development of effective methods for the treatment of severe cases. We aimed to describe clinical outcomes and changes in inflammatory markers in Polish patients treated with tocilizumab. The medical charts of SARS-CoV-2-positive patients treated...

Cite
Olewicz-Gawlik A, Ginter-Matuszewska B, Kamiński M, et al. Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study. J Clin Med. 2021;11(1)doi: 10.3390/jcm11010107.
Olewicz-Gawlik, A., Ginter-Matuszewska, B., Kamiński, M., Adamek, A., Bura, M., Mozer-Lisewska, I., & Kowala-Piaskowska, A. (2021). Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study. Journal of clinical medicine, 11(1), . https://doi.org/10.3390/jcm11010107
Olewicz-Gawlik, Anna, et al. "Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study." Journal of clinical medicine vol. 11,1 (2021). doi: https://doi.org/10.3390/jcm11010107
Olewicz-Gawlik A, Ginter-Matuszewska B, Kamiński M, Adamek A, Bura M, Mozer-Lisewska I, Kowala-Piaskowska A. Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study. J Clin Med. 2021 Dec 25;11(1). doi: 10.3390/jcm11010107. PMID: 35011848.
Copy Download .nbib Format: NLM
Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma.

Archives of medical science : AMS

Kasprzak A, Rogacki K, Adamek A, Sterzyńska K, Przybyszewska W, Seraszek-Jaros A, Helak-Łapaj C, Pyda P.
PMID: 29181057
Arch Med Sci. 2017 Oct;13(6):1269-1280. doi: 10.5114/aoms.2017.65272. Epub 2017 Jan 19.

INTRODUCTION: The role of Wnt/ β -catenin signaling pathway in HCV-associated hepatocellular carcinogenesis is still unknown.MATERIAL AND METHODS: This study aimed to perform quantitative analysis of immuno- and hybridocytochemical expression of β -catenin, E- and N-cadherins and HCV proteins...

Cite
Kasprzak A, Rogacki K, Adamek A, et al. Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma. Arch Med Sci. 2017;13(6):1269-1280doi: 10.5114/aoms.2017.65272.
Kasprzak, A., Rogacki, K., Adamek, A., Sterzyńska, K., Przybyszewska, W., Seraszek-Jaros, A., Helak-Łapaj, C., & Pyda, P. (2017). Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma. Archives of medical science : AMS, 13(6), 1269-1280. https://doi.org/10.5114/aoms.2017.65272
Kasprzak, Aldona, et al. "Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma." Archives of medical science : AMS vol. 13,6 (2017): 1269-1280. doi: https://doi.org/10.5114/aoms.2017.65272
Kasprzak A, Rogacki K, Adamek A, Sterzyńska K, Przybyszewska W, Seraszek-Jaros A, Helak-Łapaj C, Pyda P. Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma. Arch Med Sci. 2017 Oct;13(6):1269-1280. doi: 10.5114/aoms.2017.65272. Epub 2017 Jan 19. PMID: 29181057; PMCID: PMC5701691.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries